Farxiga significantly reduced hospitalisation for heart failure
or CV death in a broad patient population with type-2 diabetes
in the landmark DECLARE-TIMI 58 trial
Fewer MACE events observed with Farxiga vs. placebo,
but this finding did not reach statistical significance
No imbalance in amputations, fractures, bladder cancer
or Fournier's gangrene with Farxiga vs. placebo
https://www.investegate.co.uk/astrazene ... 00049744G/
And;
US FDA accepts regulatory submission for Lynparza
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Priority Review for the use of Lynparza (olaparib) tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2019.
https://www.investegate.co.uk/astrazene ... 05039743G/